By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Actavis 

Morris Corporate Center III
400 Interpace Parkway
Parippany  New Jersey  07054  U.S.A.
Phone: 1-862-261-7000 Fax: n/a


SEARCH JOBS

Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland.

Actavis is the world’s third-largest generics prescription drug manufacturer, with more than 750 products marketed globally through operations in more than 60 countries. Actavis’ global branded pharmaceutical business develops and markets products principally in Urology and Women’s Health, and is committed to developing and marketing biosimilars products in Women’s Health, Oncology and other therapeutic categories. In addition, Actavis is the fourth-largest U.S. generic pharmaceutical product distributor through its Anda, Inc. business, and also develops and out-licenses generic pharmaceutical products outside of the U.S. through its Medis third-party business.

"Twice As" Video

"Our Winning Way" Video


Key Statistics


Email: actavis@actavis.com
Ownership: Public

Web Site: Actavis
Employees:
Symbol: ACT
 



Industry
Pharmaceutical






Company News
Actavis (ACT) Blood Pressure Pill Not Backed By FDA Advisers 9/10/2014 6:41:48 AM
Actavis (ACT) Announces FDA Acceptance Of The NDA Filing For Ceftazidime-Avibactam, A Qualified Infectious Disease Product 9/5/2014 10:33:55 AM
Actavis (ACT) Announces FDA Acceptance For Filing Of NDA For Eluxadoline 9/2/2014 11:40:01 AM
Actavis (ACT) To Present At Morgan Stanley (MST) Global Healthcare Conference 2014 8/27/2014 8:16:15 AM
Actavis (ACT) Confirms Generic Neupro® Patent Challenge 8/25/2014 8:13:44 AM
Pfizer (PFE) Eyes Possible Actavis (ACT) Bid Whilst Weighing Next Steps Over AstraZeneca PLC (AZN) 8/21/2014 5:50:11 AM
Actavis (ACT) Reports Positive Top-Line Data From Two Ceftazidime-Avibactam Late-Stage Trials 8/19/2014 6:57:27 AM
Medicines360 And Actavis (ACT) Announce FDA Acceptance For Filing Of NDA For Levosert™ IUD 7/21/2014 12:07:21 PM
Actavis (ACT) Confirms Generic Diclegis® Patent Challenge 7/14/2014 9:00:59 AM
Actavis (ACT) Execs Bag As Much As $186 Million In Merger Success Awards 7/9/2014 11:01:06 AM
12345678910...
//-->